Soft Mist Inhalers SMI

Soft Mist Inhalers SMI Market Outlook

The global Soft Mist Inhalers (SMI) market is poised for significant growth, with a projected market size expected to reach approximately USD 2.5 billion by 2035, expanding at a compound annual growth rate (CAGR) of around 7.5% during the forecast period from 2025 to 2035. The rise in chronic respiratory diseases, including asthma and chronic obstructive pulmonary disease (COPD), is a primary driver behind this market expansion. Furthermore, the growing preference for patient-friendly inhalation devices that ensure effective drug delivery and improved patient adherence is also contributing to the increasing demand for soft mist inhalers. The recent technological advancements that enhance device efficacy and user experience are expected to bolster market growth in the coming years. Additionally, the increasing incidence of respiratory disorders in the aging population is another critical factor propelling the market forward.

Growth Factor of the Market

The growth of the Soft Mist Inhalers market is significantly influenced by several factors that enhance their adoption across various healthcare settings. Firstly, increased awareness and diagnosis of respiratory diseases, fueled by improved access to healthcare, are leading to a higher number of prescriptions for inhalation therapies. As healthcare professionals continue to recognize the benefits of soft mist inhalers in delivering medication effectively, the market demand is likely to rise correspondingly. Moreover, technological advancements that enhance the design and performance of these devices, such as the integration of smart technology for tracking medication usage, are driving patient engagement and adherence. The growing trend towards home healthcare solutions is also making soft mist inhalers a preferred choice for many patients, as they offer convenience and ease of use in non-clinical settings. Finally, supportive government initiatives and increased healthcare funding for respiratory health programs are contributing significantly to the market’s growth potential.

Key Highlights of the Market

• Expected market growth to USD 2.5 billion by 2035.
• CAGR of approximately 7.5% during the forecast period 2025-2035.
• Technological advancements enhancing device efficacy.
• Increased awareness and diagnosis of respiratory diseases.
• Growing trend towards home healthcare solutions.

By Product Type

Respimat

Respimat inhalers represent a significant segment of the soft mist inhalers market, distinguished by their innovative design that utilizes a unique mechanism for drug delivery. These inhalers offer a soft mist that allows for efficient medication absorption into the lungs, significantly improving patient outcomes for those suffering from chronic respiratory conditions. The Respimat technology is known for its ability to produce a fine aerosol that is less dependent on the patient's inhalation technique compared to traditional metered-dose inhalers, making it an excellent option for individuals who may struggle with proper inhalation. The increasing adoption of Respimat inhalers can be attributed to their proven efficacy, ease of use, and the convenience they offer, particularly for elderly patients and those with limited dexterity. As a result, the Respimat segment is poised for consistent growth, driven by rising asthma and COPD prevalence worldwide.

Soft Mist Inhaler with Spacer

Soft Mist Inhalers with spacers are gaining traction within the market due to their ability to enhance drug delivery and improve patient compliance, particularly among pediatric and elderly patients. The spacer device aids in the proper inhalation of the medication by allowing the aerosol to stabilize before entering the patient's mouth, reducing the chance of medication being deposited in the oropharynx. This results in more effective lung deposition of medication, thereby improving therapeutic outcomes. The growing awareness and acceptance of these devices, particularly among healthcare providers, are expected to contribute to their increasing popularity. Additionally, the enhanced safety profile and the ease with which they can be used by patients of all ages support their demand in the market. With the rising focus on user-friendly medical devices, the Soft Mist Inhaler with Spacer segment is set to experience robust growth in the coming years.

By Application

Asthma

The application of soft mist inhalers in asthma management is a critical segment of the market, reflecting the increasing prevalence of asthma globally. Asthma is a chronic respiratory condition characterized by inflammation and narrowing of the airways, leading to breathing difficulties. Soft mist inhalers provide an effective method for delivering bronchodilators and corticosteroids, which are essential in managing asthma symptoms. The advantages of soft mist inhalers, such as their ability to provide a consistent dose and enhanced patient experience, are driving their adoption among asthma patients. Furthermore, educational initiatives aimed at promoting awareness of effective asthma management strategies are expected to bolster the demand for soft mist inhalers in this application segment. As healthcare systems strive to improve asthma management and patient compliance, this segment is likely to witness significant growth in the foreseeable future.

COPD

Chronic obstructive pulmonary disease (COPD) is another major application area for soft mist inhalers, accounting for a substantial share of the market. COPD comprises a group of progressive lung diseases, including emphysema and chronic bronchitis, that result in breathing difficulties and reduced airflow. Soft mist inhalers offer an effective delivery mechanism for long-acting bronchial dilators and anti-inflammatory medications, which are crucial for managing COPD symptoms and improving quality of life. The increasing awareness of COPD management and the benefits of using soft mist inhalers for medication delivery are leading to higher acceptance among patients. As the global population continues to age and the number of COPD cases rises, the demand for soft mist inhalers in this application segment is expected to grow steadily, supported by a focus on improving patient outcomes and reducing hospital admissions due to exacerbations.

Cystic Fibrosis

Cystic fibrosis (CF) is a genetic disorder that severely affects the lungs and digestive system, often requiring complex treatment regimens. The use of soft mist inhalers in the management of cystic fibrosis represents a promising application area, as these devices can deliver high doses of medications, including antibiotics and mucolytics, directly to the lungs. The soft mist technology allows for more efficient medication absorption, which is vital for patients with CF who require long-term and consistent treatment. With the rise in awareness and diagnosis of cystic fibrosis, combined with advancements in inhalation technologies, the demand for soft mist inhalers in this application segment is projected to rise. The increasing emphasis on personalized medicine and tailored treatment plans is also expected to drive the growth of soft mist inhalers for cystic fibrosis management.

Others

In addition to asthma, COPD, and cystic fibrosis, soft mist inhalers are utilized in various other applications, including the treatment of respiratory infections and allergies. This segment encompasses a wide range of conditions that require effective inhalation therapies. The versatility of soft mist inhalers in delivering different types of medications, such as corticosteroids, bronchodilators, and antihistamines, makes them suitable for treating diverse respiratory conditions. The growing prevalence of respiratory diseases, particularly in urban areas, along with rising awareness regarding the benefits of soft mist inhalers, is likely to contribute to the growth of this segment. As healthcare providers continue to explore innovative treatment options, soft mist inhalers are expected to gain traction across multiple respiratory applications in the coming years.

By Distribution Channel

Hospital Pharmacies

Hospital pharmacies play a crucial role in the distribution of soft mist inhalers, especially for patients with acute respiratory conditions requiring immediate medical attention. These pharmacies are essential in ensuring that hospital patients receive the right medications promptly, which often includes soft mist inhalers as part of their treatment regimen. The accessibility to specialized inhalation therapies and the presence of healthcare professionals who can offer guidance and education on proper inhaler use significantly enhance the patient experience in hospital settings. With the growing focus on quality care and patient safety, hospital pharmacies are expected to continue their pivotal role in the distribution of soft mist inhalers, fostering improved outcomes for patients facing respiratory challenges.

Retail Pharmacies

Retail pharmacies serve as a vital distribution channel for soft mist inhalers, providing patients with easy access to essential respiratory medications. These pharmacies play a significant role in managing chronic respiratory diseases by offering various inhalation devices, including soft mist inhalers, to patients in the community. The convenience of retail pharmacies, combined with the ability for consumers to consult with pharmacists regarding their medication needs, enhances patient adherence and education regarding proper inhaler usage. As awareness of respiratory conditions rises and patients seek more accessible treatment options, retail pharmacies are poised to experience increased demand for soft mist inhalers as part of their respiratory care offerings.

Online Pharmacies

With the rise of e-commerce and digital health solutions, online pharmacies have emerged as an increasingly popular distribution channel for soft mist inhalers. The convenience of purchasing medications from the comfort of home, along with discreet delivery options, has contributed to the growing appeal of online pharmacies, particularly among patients with chronic respiratory conditions who may prefer not to visit physical stores. Online pharmacies also allow for easy price comparison and access to a wider range of products, making it easier for patients to obtain the necessary inhalers. As regulatory frameworks evolve to support the safe sale of prescription medications online, the soft mist inhalers market is expected to benefit from the continued growth of this distribution channel.

By Ingredient Type

Albuterol

Albuterol is a commonly used bronchodilator that serves as a critical ingredient in many soft mist inhalers for managing respiratory conditions such as asthma and COPD. Its effectiveness in relaxing airway muscles and opening air passages allows for improved airflow and relief from symptoms. The high demand for albuterol in the treatment of acute bronchospasm has led to its widespread incorporation in soft mist inhaler formulations. As the number of asthma and COPD patients increases globally, the market for soft mist inhalers containing albuterol is expected to grow consistently. The ongoing research and development efforts aimed at enhancing the formulation of albuterol also contribute to its sustained relevance in the soft mist inhalers market.

Ipratropium

Ipratropium is another essential ingredient commonly found in soft mist inhalers, particularly for patients with COPD. As an anticholinergic bronchodilator, ipratropium works by relaxing the muscles around the airways, facilitating easier breathing. The inclusion of ipratropium in soft mist inhalers allows for effective management of respiratory symptoms and plays a critical role in combination therapies. The growing prevalence of COPD and the rising need for effective management strategies are driving the demand for soft mist inhalers that incorporate ipratropium. With ongoing clinical studies demonstrating the benefits of combination therapies, the market for inhalers featuring ipratropium is expected to expand alongside the overall growth of the respiratory inhalation market.

Salmeterol

Salmeterol, a long-acting β2-adrenergic agonist, is often combined with corticosteroids in soft mist inhalers for the management of asthma and COPD. Its role in providing sustained bronchodilation helps improve lung function and reduce the frequency of exacerbations. The growing recognition of the importance of long-term management strategies in chronic respiratory diseases is contributing to the increased adoption of soft mist inhalers containing salmeterol. As patients and healthcare providers continue to prioritize effective and prolonged symptom control, the salmeterol segment of the market is poised for growth. The development of combination therapies featuring salmeterol in soft mist inhalers is also expected to enhance the overall treatment landscape for respiratory conditions.

Formoterol

Formoterol, similar to salmeterol, is a long-acting bronchodilator frequently utilized in soft mist inhalers for asthma and COPD management. Known for its rapid onset of action and prolonged effects, formoterol is often used in conjunction with inhaled corticosteroids to provide comprehensive symptom control. As the understanding of the benefits of combination therapy grows, the incorporation of formoterol into soft mist inhaler formulations is likely to rise. The increasing prevalence of respiratory diseases and the emphasis on effective management strategies are expected to drive demand for inhalers featuring formoterol, reinforcing its importance in the overall soft mist inhalers market.

Others

The "Others" category under ingredient types encompasses a variety of active compounds used in soft mist inhalers, including combinations of different bronchodilators and anti-inflammatory agents tailored to meet the diverse needs of patients with respiratory conditions. The versatility of soft mist inhalers allows for the formulation of custom therapies that address specific patient requirements, enhancing their effectiveness in managing complex respiratory disorders. The evolving landscape of respiratory drug development is also contributing to the introduction of novel ingredients and formulations in soft mist inhalers, further driving growth in this segment. As the demand for personalized medicine increases, the "Others" segment is expected to expand, reflecting the ongoing innovations in inhaler technology and formulation science.

By Region

The regional analysis of the soft mist inhalers market reveals varying growth dynamics across different geographical areas. North America is anticipated to lead the market, driven by the high prevalence of respiratory diseases, advanced healthcare infrastructure, and robust regulatory frameworks supporting inhalation therapies. The region's market is projected to grow at a CAGR of approximately 7.2%, with increasing demand for innovative inhalation devices and a focus on improving patient outcomes. Furthermore, the presence of major pharmaceutical companies and continuous research and development efforts in North America contribute to its dominance in the global soft mist inhalers market.

In Europe, the soft mist inhalers market is also expected to experience substantial growth, fueled by rising awareness of respiratory disorders and the increasing adoption of advanced inhalation technologies. The region is characterized by stringent regulations that promote the development of effective and safe inhalation devices. As European countries continue to invest in healthcare and prioritize respiratory health initiatives, the demand for soft mist inhalers is likely to rise. Asia Pacific is emerging as a significant market for soft mist inhalers, driven by the rising population, urbanization, and increasing healthcare accessibility. The growing prevalence of asthma and COPD in the region further supports market growth, with a focus on adopting innovative healthcare solutions to improve patient care. Latin America and the Middle East & Africa are also witnessing gradual growth in the soft mist inhalers market, as awareness of respiratory diseases increases and healthcare systems evolve to meet patient needs. Overall, the regional landscape of the soft mist inhalers market reflects a diverse array of growth opportunities, driven by localized factors.

Opportunities

The Soft Mist Inhalers market presents numerous opportunities for growth, particularly as healthcare systems worldwide prioritize improved respiratory care. One significant opportunity lies in the ongoing research and development efforts aimed at enhancing the design and functionality of inhalation devices. Innovations such as the integration of digital technology into inhalers for tracking medication usage and adherence can significantly enhance patient engagement and medication management. This is particularly relevant as healthcare providers increasingly recognize the importance of personalized medicine and tailored treatment plans for patients with chronic respiratory conditions. Additionally, the rise in telemedicine and remote patient monitoring opens avenues for the development of connected inhalation devices that provide real-time data to healthcare professionals, further driving the adoption of soft mist inhalers.

Another opportunity within the market arises from the increasing prevalence of respiratory diseases, particularly in developing and emerging economies. As more patients are diagnosed with conditions such as asthma and COPD, the demand for effective inhalation therapies will correspondingly rise. Governments and healthcare organizations are beginning to recognize the need for accessible and affordable treatment options, which could lead to greater investments in respiratory health initiatives. Furthermore, raising awareness among healthcare professionals and patients regarding the benefits of soft mist inhalers in managing respiratory conditions serves as a catalyst for market growth. By implementing educational programs and initiatives that emphasize proper inhaler usage and management techniques, the potential for expanding the soft mist inhalers market becomes increasingly tangible.

Threats

The Soft Mist Inhalers market faces several threats that could impact its growth trajectory. One of the key challenges is the presence of alternative inhalation devices, such as metered-dose inhalers (MDIs) and dry powder inhalers (DPIs), which compete for market share. These alternatives, while effective, have distinct benefits that may appeal to different patient populations. For instance, some patients may prefer the perceived simplicity and portability of MDIs, leading to potential competition for soft mist inhalers. Additionally, the growing trend towards generic medications poses a threat to branded inhaler products, as the introduction of lower-cost alternatives may lead to price competition and reduced profit margins for manufacturers. The market must also contend with issues related to regulatory approvals and the need for continuous compliance with stringent safety standards, which can create barriers for new entrants and impede innovation.

Another significant threat to the soft mist inhalers market is the potential for supply chain disruptions, particularly in light of global events that can impact manufacturing and distribution processes. Factors such as geopolitical tensions, natural disasters, or pandemics can lead to interruptions in the supply of active pharmaceutical ingredients and finished inhalation devices. These disruptions can adversely affect the availability of soft mist inhalers in the market, resulting in decreased access for patients reliant on these products for their respiratory care. Consequently, manufacturers must be proactive in assessing their supply chain vulnerabilities and implementing strategies to mitigate risks associated with potential disruptions.

Competitor Outlook

• Boehringer Ingelheim
• GlaxoSmithKline
• Novartis
• AstraZeneca
• Teva Pharmaceuticals
• Roche
• Merck & Co.
• Sun Pharmaceutical Industries
• Mylan N.V.
• Pfizer Inc.
• Hikma Pharmaceuticals
• Sanofi
• Chiesi Farmaceutici
• Takeda Pharmaceutical Company
• Viatris

The competitive landscape of the Soft Mist Inhalers market is characterized by the presence of several leading pharmaceutical companies that are actively engaged in the development and marketing of innovative inhalation devices. These companies are primarily focused on research and development to introduce new formulations and technologies that enhance the effectiveness of soft mist inhalers. Established players in the market, such as Boehringer Ingelheim and GlaxoSmithKline, hold significant market shares due to their extensive portfolios and strong brand recognition. Their ongoing investment in R&D, coupled with strategic partnerships and collaborations, positions them well to remain competitive in this rapidly evolving market. Additionally, the rise of generic manufacturers, such as Mylan N.V. and Teva Pharmaceuticals, is intensifying competition as they seek to provide cost-effective alternatives to branded soft mist inhalers, catering to a broader patient demographic.

Companies are also leveraging strategic mergers and acquisitions to strengthen their market position and expand their product offerings. For instance, the acquisition of smaller firms specializing in inhalation technologies enables larger companies to enhance their capabilities and gain access to innovative products. Furthermore, the growing focus on personalized medicine and tailored therapies has prompted manufacturers to explore collaborations with technology firms to develop smart inhalers that can track patient adherence and optimize treatment regimens. This trend towards digital health solutions is reshaping the competitive landscape, as companies strive to develop integrated systems that improve patient engagement and healthcare outcomes.

In terms of market outlook, the competitive dynamics are expected to evolve as new entrants emerge and established players adapt to changing regulatory environments and patient needs. Innovations in inhalation technology, such as soft mist devices incorporating digital features for enhanced tracking and adherence, will be pivotal in differentiating products in the market. Additionally, the ongoing emphasis on sustainability and environmentally friendly packaging solutions may influence consumer preferences, prompting companies to rethink their product designs and marketing strategies. As the soft mist inhalers market continues to expand, the competition among key players is likely to intensify, driven by the need to address unmet patient needs and deliver effective respiratory care solutions.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Roche
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Sanofi
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Viatris
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Novartis
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Mylan N.V.
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 AstraZeneca
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Merck & Co.
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Pfizer Inc.
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 GlaxoSmithKline
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Chiesi Farmaceutici
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Boehringer Ingelheim
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Teva Pharmaceuticals
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Hikma Pharmaceuticals
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Sun Pharmaceutical Industries
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Takeda Pharmaceutical Company
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Soft Mist Inhalers SMI Market, By Application
    • 6.1.1 Asthma
    • 6.1.2 COPD
    • 6.1.3 Cystic Fibrosis
    • 6.1.4 Others
  • 6.2 Soft Mist Inhalers SMI Market, By Product Type
    • 6.2.1 Respimat
    • 6.2.2 Soft Mist Inhaler with Spacer
  • 6.3 Soft Mist Inhalers SMI Market, By Ingredient Type
    • 6.3.1 Albuterol
    • 6.3.2 Ipratropium
    • 6.3.3 Salmeterol
    • 6.3.4 Formoterol
    • 6.3.5 Others
  • 6.4 Soft Mist Inhalers SMI Market, By Distribution Channel
    • 6.4.1 Hospital Pharmacies
    • 6.4.2 Retail Pharmacies
    • 6.4.3 Online Pharmacies

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Soft Mist Inhalers SMI Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Soft Mist Inhalers SMI market is categorized based on

By Product Type

• Respimat
• Soft Mist Inhaler with Spacer

By Application

• Asthma
• COPD
• Cystic Fibrosis
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Ingredient Type

• Albuterol
• Ipratropium
• Salmeterol
• Formoterol
• Others

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Boehringer Ingelheim
• GlaxoSmithKline
• Novartis
• AstraZeneca
• Teva Pharmaceuticals
• Roche
• Merck & Co.
• Sun Pharmaceutical Industries
• Mylan N.V.
• Pfizer Inc.
• Hikma Pharmaceuticals
• Sanofi
• Chiesi Farmaceutici
• Takeda Pharmaceutical Company
• Viatris